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In the present review, an attempt is made to crystallize, from the extensive
and often contradictory literature on hypertension, a rational approach to
the management of the hypertensive patient.
On the basis of criteria regarding etiology and prognosis outlined in
Parts I and II, a plan of medical treatment is presented in Part III which
is particularly concerned with the use of the newer "anti-hypertensive"
drugs. Some of the results of drug therapy are summarized from the
literature as well as from our own clinical experience with 56 patients.
PART I. EVALUATION OF THE DEFINITION, ETIOLOGY, AND PROG-
NOSIS OF HYPERTENSION
1. EVALUATION OF THE SIGNIFICANCE OF AN APPARENTLY HIGH BLOOD PRESSURE
READING
There are several points which must be considered before a blood
pressure reading can be classified as "normal" or "abnormal" for a given
patient:
a. The method of measurement. Auscultatory methods for measuring
blood pressure underestimate direct methods by increasing increments as
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the level of blood pressure rises.' Variations in the relation between the
arm and sphygmomanometric cuff contribute further error to the deter-
mination as does the uncertainty as to which phase of the Korotkoff sounds
is acceptable as the truest indication of the diastolic blood pressure.8 101, 30
(Recent evidence favors use of the muffling of sounds rather than their dis-
appearance.10") In addition, the position of the patient has a variable effect on
the blood pressure which is of particular importance in patients under treat-
ment with hypotensive drugs. Even without medication, the blood pressure
of the standing patient may be as much as 25/10 mm.Hg lower than that
of the same individual when supine.
b. The definition of "normal blood pressure." The limits of "normal"
blood pressure remain ill-defined.2' On the one hand, upper limits of normal
have been based on statistical averages of mixed groups which include
unknown numbers of hypertensives.102 According to such data, more than
50%o of patients past the age of 50 years have blood pressures over 140/90.
On the other hand, the value of about 140/90 has been set as the upper
limit of normal on the basis of insurance groups from which higher values
tend to have been pre-excluded.' Until better data, or more practical and
safe methods of controlling blood pressure, are available, it may be best to
consider values between 140/90 and the higher averages advocated by
Master as "suspicious," but unproven hypertension.
c. Physiological variations of the blood pressure. The normal slight labil-
ity of the blood pressure is exaggerated in anxious patients so that diastolic
as well as systolic hypertension may be present with excitement, or during
initial blood pressure determinations, and may be absent in most subsequent
measurements. Some of these "hyper-reacting" individuals may be more
than usually likely to exhibit later hypertension.8263 In any event, many
determinations of the blood pressure, under as restful conditions as possible,
may be necessary in some patients to establish the usual range and average
value of their blood pressure. Such data are best obtained as unobtrusively
as possible in order to avoid overemphasizing the importance of the level
and variations of blood pressure to the patient.
d. Diastolic vs. systolic values. Diastolic elevation of blood pressure, with
which systolic elevation is usually associated, is of primary importance in
relation to hypertensive vascular disease. An elevated systolic with normal
or low diastolic value is not an indication of the more serious type of hyper-
tension,* but may be associated with a variety of circumstances in which
*Except when severe aortic insufficiency is superimposed on hypertension which
would otherwise be of the diastolic type.
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stroke volume or diastolic "run-off" is increased, or in which the elasticity
or capacity of the large arteries is diminished. Systolic hypertension may be
found with the high stroke volume of excitement, severe anemia, hyper-
thyroidism, bradycardia, marked peripheral vasodilatation, aortic insuf-
ficiency, and A-V shunts; or with aortic abnormalities such as coarctation,
arteriosclerosis and obliterative endarteritis. (The latter process may, by
involving the renal artery, cause more serious diastolic hypertension, as
indicated below.)
11. ETIOLOGICAL EVALUATION
The finding of persistent diastolic hypertension imposes an obligation on
the part of the physician to search, as briefly or as extensively as seems
warranted in each instance, for one or more of the remediable etiological
factors which may be involved in producing the hypertension. However, it
is important to avoid overemphasizing to the patient, by an extensive
investigation, the seriousness of an illness for which no truly remediable
cause may be found and for which the available nonspecific therapy may
well be unsatisfactory, or even unnecessary.
In general the more obviously serious the disease is, the more it war-
rants diligent search for a specific etiology, but at the same time it must
be borne in mind that hypertension, due at first to a completely remediable
primary cause (e.g., an ischemic kidney), may eventually become self-
perpetuating even if the primary cause is removed. Early diagnosis of such
a primary cause is therefore very important.
Diagram 1 illustrates the interplay of some of the physiological and patho-
logical mechanisms which have been implicated in the production of hyper-
tension. A detailed review of the experimental data upon which the diagram
is based would be outside the scope of this presentation. The small numbers
have therefore been included in order to indicate references which document
the relations that are indicated in the diagram and summarized as follows:
a. The hemodynamic basis of hypertension is (with the exception of aortic
coarctation) arteriolar obstruction to blood flow, caused by vasoconstriction
and organic vascular disease (Diagram 1, No. 14), the cardiac output
remaining normal. The question (see Diagram 1) of whether hypertension
may, in itself, cause vascular disease is discussed in subsequent pages at
length.
b. The renal vessels have been set aside from other peripheral vessels
because of the experimental and clinical evidence indicating their particular
importance to the problem of hypertension.
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c. Part of the arteriolar abnormality may in many cases arise as a result
of imbalance or excesses of depressor and pressor substances circulating in
the blood. These have been identified as originating in the brain (Diagram
1, No. 1), the kidney (Diagram 1, Nos. 12 and 13), the liver (Diagram 1,
No. 11), the endocrine organs (Diagram 1, Nos. 7, 8 and 9), and from
unknown sources (Diagram 1, No. 12).
DIAGRAM I. SCHEMA ILLUSTRATING THE ETIOLOGY OF HYPERTENSION
Legend: The relations indicated in the diagram are labeled with numbers which refer
to references listed alphabetically at the end of this review, as follows:
(1) Page, 1951
(2) Weiss, 1942; Binger, et al., 1945; Gressel, et al., 1949
(3) Weiss, 1942; Hamilton and Pickering, 1954
(4) Burch, et al., 1942; Brust, et al., 1951
(5) Heymans, et al., 1951; Kezdi, 1953
(6) Von Euler and Liljestrand, 1946
(7) Kempner, 1948; Hatch, et al., 1954
(8) Handler and Bernheim, 1950; Findley, 1949
(9) Selye, 1950; Perera, 1950; Merrill, 1952
(10) Whitelaw and Smithwick, 1951
(11) Zweifach and Shorr, 1948
(12) Schroeder and Olsen, 1950; Corcoran, et al., 1951
(13) Waters, 1948
(14) Bradley, 1948
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d. Neurogenic factors may play a role in the arteriolar vasoconstriction
(Diagram 1, No. 10) as a result of a variety of stimuli (Diagram 1, Nos.
2-6).
e. The arterioles themselves may change in morphology or in reactivity
to humoral pressor or neurogenic factors as a result of aging, heredity, or
endocrine influences (Diagram 1, No. 9).
Many of the mechanisms outlined in the diagram are not susceptible to
clinical evaluation. However, appropriate diagnostic procedures may be
directed toward the following diseases which may give rise to hypertension:
1. Renal disease. Urinalysis, urine cultures, urine function tests (PSP,
NPN, concentration test, inulin and PAH clearances), and the I-V pyelo-
gram, correlated with the clinical history, will fairly well identify glomerular
nephritis, pyelonephritis, and polycystic kidneys.' Although a good case can
be made for a close relationship between pyelonephritis and associated
hypertension,"2 convincing statistical evidence to the contrary has been pre-
sented."2' Antibiotic treatment of active pyelonephritis may prevent further
renal damage but is quite unlikely to eliminate the associated hypertension.
'The finding of polycystic kidneys usually warrants some shift in emphasis
from the problem of hypertension to that of gradually progressive renal
failure. Although 75% of adult patients with this disease have hypertension,
only about 5% have more than grade II retinopathy (see Part II below)
and only 30%o die as a result of hypertension or its effects." Unilateral renal
disease may be particularly suspected if the hypertension is severe, of recent
onset, and in a young or elderly patient.' If the initial renal examination
yields further evidence of this possibility, retrograde urography, aortogra-
phy, and, finally, unilateral nephrectomy may be warranted in view of the
scattered reports of the rare cure of severe hypertensive vascular disease by
extirpation of unilateral renal disease-particularly pyelonephritis, hydro-
nephrosis, and partial renal arterial obstruction.'' '' lM l2l It is well to
realize that hypertension related to disease of one kidney not only is quite
rare, but also is persistent after nephrectomy (i.e., is already self-perpetuat-
ing by the time of nephrectomy) in 50-75%o of cases." On this basis, only
urologic indications for nephrectomy (especially the finding of one essen-
tially nonfunctioning kidney in the presence of good contralateral function)
are accepted by some writers,' although in several cases hypertension has
been relieved by removal of an ischemic, but still functioning, kidney.="'""
2. Adrenal disease. Secretions of the adrenal cortex appear to be neces-
sary for the preservation of normal vascular reactivity1w and for the
maintenance of normal blood pressure.'7 Hypotension is a cardinal symptom
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of Addison's disease. Hypertension is a frequent manifestation of the
classical Cushing's syndrome, as well as of the "pseudo-Cushing's" syn-
drome in women described by Schroeder,'" and is occasionally seen during
DOCA or ACTH therapy (Cortisone being a less frequent offender),
particularly in patients with antecedent hypertensive tendencies"' and
renal disease." Hypertension in these circumstances may be much ameli-
orated or eliminated by salt restriction, and even more effectively by re-
moval of the source of the cortical hormones, where this is possible. The
adrenal medulla is normally concerned with blood pressure only under
"emergency" conditions when its secretion, containing predominantly
epinephrine (80% vs. 20% norepinephrine), causes elevation of the systolic
pressure with very little change in the diastolic pressure.' However, rare
pheochromocytomata (usually of the adrenal medulla) may cause intermit-
tent or continuous diastolic hypertension associated with a clinical picture
dependent, at least in part, on the relative proportions of epinephrine and
norepinephrine in their secretions. The hypertension is often severe and
may occur with normal heart rate, blood sugar, and basal metabolic rate,
particularly-but not necessarily-when norepinephrine predominates in
the tumor. The most direct tests for pheochromocytomata, i.e., the assay of
blood and urine for epinephrine and norepinephrine, are not ordinarily
available, although promising chemical methods for screening urines for
these compounds have been recently described." However, in spite of occa-
sional false positive and negative results, several practical pharmacological
tests are useful in detecting pheochromocytomata in selected hypertensive
patients.'8 Present preference seems to be for the Regitine test" in cases of
persistent hypertension, because of the absence of severe side reactions seen
with benzodioxane, and for the mecholyl test" (with atropine) in cases of
paroxysmal hypertension seen during a normotensive phase, because of the
greater incidence of side reactions and false positive results with the hista-
mine test. In cases showing distinctly positive tests by two methods or on
two occasions, examination of the adrenal area by means of I-V pyelograms
and/or presacral air studies1' may be confirmatory. Although the finding of
a pheochromocytoma is extremely important for the patient so involved, the
rarity of the disease is such that a great number of negative tests in patients
with persistent hypertension must, on the average, be performed before a
pheochromocytoma is found. This small "return," the nuisance (to say
nothing of the possible psychic trauma to the patient) of an occasional false
positive test, and the knowledge that hypertension may persist (in 7 of 12
cases in one series'1) after operative removal of the rare tumor which is
found, all raise some doubt as to the usefulness of using the pharmacologi-
456
Volume 27, June 1955Evaluation and management of hypertension GOODYER, ROSENTHAL,
JAEGER
cal tests in hypertensives in whom the possibility of pheochromocytomata is
not suggested on clinical grounds" (crises, elevated BMR, glycosuria,
severe sweating, "paroxysmal nephritis""), or in whom the hypertension
is not severe.
3. Coarctation of the aorta, another uncommon cause of hypertension, is
nevertheless to be carefully considered in every case because of its potential
remediability. This possibility can be evaluated by the simple procedure of
palpating the pulses (and, if necessary, by measuring the blood pressure)
in the lower extremities. Several diseases which also diminish or eliminate
the femoral pulses, such as obliterative aortic arteriosclerosis (Leriche's
syndrome) or dissecting aortic aneurysm, should cause no confusion, since
they have very different clinical backgrounds. Ribnotching and a character-
istic aortic cleft (at the site of coarctation) in the ordinary chest film are
pathognomonic.
4. Toxemia of pregnancy is characterized by a rising diastolic blood
pressure, increasing edema, and albuminuria in the young, previously nor-
motensive, primigravid patient during the 7th-8th month of pregnancy.' In
patients with pre-existent, persistent hypertension, indicated by history and
by the presence of vascular changes in the fundi, toxemia tends to be more
frequent (40-50%o), earlier in occurrence (4th-5th month), and more
severe." Many mild hypertensives do well during pregnancy, and appear
to suffer no increase in their vascular disease. However, if progressive
toxemia occurs for more than four to five weeks, subsequent persistent
hypertension (in patients previously normotensive), or prolonged exacer-
bation of pre-existent hypertension is likely.""' Therefore, therapeutic abor-
tion for severe hypertension during the first trimester, and intensive medi-
cal therapy, including salt restriction and the use of anti-hypertensive drugs
(see Part III, below), for severe toxemia or eclampsia in the later months
of pregnancy, are widely recommended.""2 88
5. Other unusual diseases which may be associated with hypertension
are listed below. Their recognition will tend to shift the emphasis of prog-
nosis and management from the hypertension to the primary disorder itself.
(a) Periarteritis nodosa
(b) Lupus erythematosis
(c) Bulbar poliomyelitis
(d) Brain tumor and increased CSF pressure
(e) Tabetic crises
(f) Porphyria
(g) Multiple myeloma.
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III. PROGNOSTIC EVALUATION
Most cases of hypertension have either no identifiable etiology, or are
associated with disease (usually renal) which is not primarily remediable.
The problem of management in each case then involves repeated re-evalua-
tion of the prospective morbidity and mortality of untreated as compared
with treated disease.
The prognosis of untreated hypertension in each patient may be esti-
mated, with only fair correctness, by a study of the initial characteristics of
the disease and the course of associated vascular disease in the CNS, heart,
and (especially) ocular fundi and kidneys. The results of the study can
then be compared (grossly, or by an appropriate "scoring" system) with
similar data reported for large series of cases in the literature."' 68' 495959587,95,108
The following initial characteristics favor the likelihood of a more benign
course: age of patient more than 50, female sex, negative family history,
relation to menopause, asymptomatic onset, prior duration for more than
10 years, diastolic values less than 120 mm.Hg, lability, absence of recent
progression, absence of vascular disease. Specific evidence of lability may be
given by spontaneous fall of the pressure to low or even normal levels when
initial anxiety of the patient has been relieved, or during an amytal sedation
test.
Data useful in estimating the extent of organic vascular disease may be
outlined as follows:
1. Fundoscopic changes (see Part II, below).
2. Renal function-initial examination of the kidneys for the presence of
disease has been described above in discussing primary renal disease. With
respect to the problem of prognosis, an evaluation of the extent of renal im-
pairment is also very important. Marked functional impairment usually in-
dicates severe, progressive disease with a poor prognosis, and the possibil-
ity of a developing malignant phase. The PSP test (indicative of renal
tubular function and blood flow), and the urine concentration test (indica-
tive of more specific tubular functions) may indicate renal impairment long
before it becomes evident via urinalysis or elevation of the NPN." Studies
of the clearances of inulin and PAH, etc., may provide even earlier and
more exact indications of the disproportionate reduction of renal blood flow
(as compared with glomerular filtration) characteristic of severe hyper-
tensive disease, but they are too burdensome to be applicable to the ordinary
case of hypertension." " Percutaneous renal biopsy is potentially much
more informative,.9 but has not yet been established as an entirely safe and
truly valuable procedure for other than a few specially selected cases.
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3. The heart. Left ventricular hypertrophy (as indicated by the electro-
cardiogram and chest film) is usually an indication of longstanding disease;
congestive heart failure (often preceded by a diastolic apical gallop) and
coronary disease (indicated by the electrocardiogram, and a history of
angina or myocardial infarction) are particularly indicative of a serious
prognosis. On the other hand, marked hypertension may persist for many
years without these evidences of cardiac damage.
4. The CNS. A cerebral vascular accident in a hypertensive patient
implies probable cerebral arterial or arteriolar disease and portends further
cerebral vascular difficulties. Hypertensive encephalopathy, characterized
by clouding of the sensorium or convulsions in the presence of extreme
elevation of the blood pressure, usually indicates a very serious prognosis in
the absence of a specific remediable cause for the hypertension. However, it
is not necessarily associated with cerebral vascular disease, may have no
neurological sequellae, and is therefore potentially completely reversible.
Hypertensive encephalopathy in experimental animals is characterized by
patchy increases in cerebral capillary permeability due to severe vaso-
spasm.'" This pathogenesis seems more reasonable than the hypothesis that
the elevated arterial pressure "breaks through" the arteriolar resistance to
be transmitted to the post-arteriolar vascular bed.82 Encephalopathy may
respond dramatically to antihypertensive drugs, particularly in the absence
of uremia, probably by direct relief of vasospasm. The malignant phase of
hypertension, in which encephalopathy is common, is of special import
because it presages death within a year.'0 It is characterized by extreme
diastolic hypertension, pathognomonic papilledema associated with severe
retinopathy, and rapidly progressive renal and cardiac impairment.
A review of the above clinical data for a given hypertensive patient
should, ideally, allow: (a) identification of the patient with one of several
grades or groups of hypertensive disease for which the average prognosis is
known; (b) comparison of this prognosis with that of the same grade of
disease subjected to each of the available methods of therapy; (c) selection
of that form of therapy which holds the most promise for improving the
prognosis of the untreated disease.
In practice, only part of this complete evaluation can be made. Published
data concerning prognosis of various groups of untreated and treated
disease based primarily on fundoscopic findings (see Part II, below), as
well as on "scoring" systems, are summarized in Table A. A representative
"scoring" system, used in this clinic, is summarized in Table B. Each listed
adverse, abnormal clinical finding is given a "severity index" from one to
four depending on the degree or innate seriousness of the abnormality. The
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total "score" for the patient at any time in the course of his disease is
derived by totalling the "severity indices." For purposes of reference to
other data, four ranges of "scores" are compared with equivalent terms or
numerical grades now in common use in the literature. The data of Tables
A and B provide some gross statistical basis for "clinical judgment" con-
cerning the choice of management for the individual patient (see Part III,
below). However, the evident gaps and inadequacies of the data, and the
TABLE B. CRITERIA FOR THE ESTIMATION OF THE SEVERITY OF HYPERTENSIVE
VASCULAR DISEASE
Severity index 1 2 3 4
Diast. pressure 96-110 111-125 126-140 >140
Duration BP 2-5 yrs. > 5 yrs.
Fundi I II III IV
CVA *
LVH (ECG or x-ray) *
Congestive failure mild severe
Coronary disease angina infarct
PSP (20)go 40-60 20-40 <20
NPN 41-60 >60
Albuminuria 1+ 2-3+ 4+
Total score = sum of individual severity indices for each category.
Total score Equivalent Term Approx. grade (Smithwick)
1-7 Mild I
8-13 Moderate II
14-20 Severe III
21 and over Malignant IV
great individual variability of the disease in individual cases, allow the
clinician to accept such prognostic evidence only with the greatest caution
and with moderate (but not blinding) scepticism.
The choice of treatment by "anti-hypertensive" agents also involves an
evaluation of the validity of the implicit assumption that hypertension is
itself productive of vascular disease. Against this assumption is the evident
discrepancy between the degree of hypertension and the extent of the
associated vascular disease. Patients with marked hypertension of unknown
etiology, or due to aortic coarctation, may exhibit no evidence of vascular
disease for many years,"7 whereas (but this is rare) the vascular disease
of "malignant" hypertension may rapidly progress in spite of the return of
the blood pressure to normal values.9" Furthermore, vascular lesions can be
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produced in animals by agents such as alylamine under conditions where
primary hypertension is avoided."T
However, there is increasing evidence which favors the view that hyper-
tension may, in itself, cause arteriolar disease:
1. Renal biopsies indicate the absence of renal vascular disease during
the early phases of essential hypertension."'
2. Neither pulmonary vascular disease nor pulmonary hypertension
occur in essential hypertension9; pulmonary hypertension due to other
causes is commonly attended by pulmonary vascular disease.'0
3. The vasculature of the unilateral Goldblatt kidney, which is pro-
tected from systemic arterial hypertension by the constricting clamp,
escapes injury, whereas vascular disease is found in the "exposed" contra-
lateral kidney.'0 Human case reports confirm this experimental observa-
tion."7 '
4. Coarctation of the aorta, which causes initially remediable hyper-
tension, may lead eventually to fixed hypertension (in 9 of 80 cases in one
series'2), associated with vascular disease.'
5. Hypertensive crises produced in dogs with sudden colloid infusions
and with epinephrine cause severe arteriolar lesions resembling those of
the malignant phase of essential hypertension.'
6. Unilateral renal disease, both in man and in the experimental animal,
may cause hypertension which is ultimately associated with contralateral
renal vascular disease.2"'0
7. Increasing evidence is accumulating of the amelioration or arrest of
the course of vascular disease in some hypertensive patients by means of
hypotensive agents which are not known to have primary effects on
metabolism or the peripheral vasculature.
These observations, although not without objections (concerned with
the possibility that an unrecognized primary "metabolic" abnormality may
cause various mixtures of hypertension and arteriolar disease), justify the
search for more effective and practical methods of blood pressure control.
In addition, even the presently available measures are useful or may affect
prognosis in ways which are not related to the prevention of vascular
disease:
1. By providing an anxious patient (and his physician) with the
reassurance that "something logical is being done," in a situation which
may appear (sometimes for good reason) to portend serious disease.
2. By relief of distressing symptoms such as headache and irritability.
3. By lightening the work load of the heart, particularly when failure is
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present or imminent, and relieving pulmonary engorgement in acute
pulmonary edema.
4. By controlling hypertensive crises such as encephalopathy and
eclampsia or pre-eclampsia.
These measures, with particular reference to drug therapy, are discussed
in detail below (Part III).
PART II. EVALUATION OF FUNDOSCOPIC FINDINGS IN HYPERTENSION
The eye is the window in the human body where the vascular system at
the arteriolar and precapillary level can be directly visualized. Much atten-
tion has therefore been paid to the vascular changes in the ocular fundus in
hypertension, which when correlated with clinical and laboratory findings
are of great importance in the estimation of prognosis. Photography,
particularly stereophotography, of the fundus has been used in this clinic
not only to evaluate the vascular changes present, but also to follow their
development and course.
NORMAL ANATOMY OF THE RETINAL VASCULATURE
Wagener and his associates"' have emphasized the importance of a
thorough knowledge of the many variations of the normal eyegrounds.
Friedenwald"' has clearly described the anatomical structure of the retinal
vessels of various sizes and has classified the pathological changes which
characterize each vessel type. The central artery, as it emerges from the
optic disc, resembles arteries of similar size in many other organs. The
intimal endothelial layer lies directly on the well-formed internal elastic
lamella and the muscular coat is well developed. As the vessel passes for-
ward, profound changes occur: the elastic lamella thins out and disappears
after the first or second bifurcation, while the muscular coat is interrupted
in increasingly wide gaps after a distance of about one disc diameter from
the disc. With the exception of the retinal vessel near the disc, the visible
vascular tree is arteriolar in character, the major branches of both arterioles
and venules coursing at the level of the nerve-fiber layer. The precapillaries,
however, can be divided into two groups: (i) the superficial group leading
to capillaries in the nerve fiber layer; and (ii) the deep group leading to
capillaries in the boundary plane between the inner nuclear and outer plexi-
form players. In general, the caliber of the retinal vessels narrows toward
the periphery, most of the step-wise change being at the points of branch-
ing. The size of a branch is normally related to the size of its parent vessel
in a ratio of 8: 10, or at most 7: 10. The choroidal circulation is made up
of large vessels which lie near the sclera and a network of capillaries near
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the retinal border. At the equator of the choroid, there is a rich anastomosis
between the anterior and posterior arterial groups. Ashton has shown1 that
the choroidal circulation can be completely injected through a single an-
terior or posterior ciliary artery, even if one artery is severed before the
injection. He suggested that localized lesions may occur in this circulation
by leakage of blood or exudate with compression of adjacent choroidal
vessels.
CLASSIFICATION OF FUNDOSCOPIC PATHOLOGY DUE TO HYPERTENSIVE DISESE
Several classifications are widely known and used, the more popular
being that of Keith, Wagener, and Barker' in which the fundus changes
are correlated with the clinical findings, or the classification of Wagener,
Clay, and Gibnerm which limits itself to a very detailed description of
retinal changes. Scheiel4u has recently outlined a very useful classification
which emphasizes the differences between hypertensive (vasospastic) and
arteriolosclerotic abnormalities, and which lends itself to reproducibility
among several observers. Whatever method is used, certain vascular
changes are recognized universally as being vasospastic and associated with
hypertension per se:
1. Angiopathy-changes of the retinal vessels
2. Retinopathy-changes of the retina itself
3. Neuropathy-changes of the disc.
1. Angiopathy. In the early stages of hypertension the retinal arterioles
may appear normal or even slightly dilated either because the retinal vessels
share less in the generalized increase in arteriolar resistance which occurs,
or because a change of the terminal arterioles cannot be appreciated oph-
thalmoscopically. In later phases of hypertension, irregularities (spasms)
of the vessel walls are noted which may or may not be superimposed upon
a more generalized narrowing. The latter is said to be characteristic of the
occasional renal hypertension of elderly patients due to atherosclerosis of
the renal arteries,TM'" and is said to correspond in degree with the severity
of the hypertension in such individuals.
2. Retinopathy. In severe hypertensive disease, damage to the capillary
wall and tissues of the retina results in extravasations and infarctions.
Flame-shaped hemorrhages, localized exudates (of the "cotton-woll" vari-
ety), and edema so diffuse as to cause retinal detachments may be evident.
In the macular region, the accumulation of fluid between the radially dis-
tributed Henle's fibers is the basis of the "macular star" (stellate figure),
which, however, is not pathognomonic of hypertension occurring in other
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pathological conditions. "Cotton-wool" patches about one-fifth the size of
the disc may occur in the optic disc and in the region of the superficial
capillary net, as a result, probably, of terminal arteriolar spasm.TM" On
section, these disc-shaped spots reveal a thickened nerve-fiber layer which
contains globular bodies called "cytoid bodies."
3. Neuropathy. When edema involves the optic nerve, it obliterates the
margins of the disc and the physiological cup, and causes the nerve head
to protrude. This finding is commonly associated with "hypertensive
encephalopathy."
As a consequence of long-standing hypertension, morphological residua
may become apparent. Hyaline material is deposited under the vascular
endothelium as far as the capillary system. The separated muscle fibers
appear as crescentic clumps and present the picture of hyaline swelling.
When fulminant, the subendothelial swelling may be accompanied by necro-
sis of the endothelial layer. These changes of arteriolar sclerosis cause a
different set of ophthalmoscopic findings than those described above as
being manifestations of hypertension per se:
1. Changes of the arteriolar light reflex
(a). Widened arteriolar light reflex. Thickening of the arteriolar wall
makes the latter a more efficient reflector and therefore widens and
brightens the light streak reflected from the vessel.
(b). "Copper wire" arterioles. Further widening of the light reflex is
combined with the redness of the underlying blood column.
(c). "Silver wire" arterioles. The vessel wall is so dense that the blood
column is obscured. The arteriole looks like a white cord.
2. Changes of the arterio-venous crossings. At these crossings, the
arterioles and venules have a common anchorage because of a common
adventitia. Normally, the venule passes undeviated closely over or under
the arteriolar branch. As a result of arteriolar sclerosis the venule may be
compressed as it crosses the arteriole, or may be deflected laterally so as to
produce an abnormal, right-angle crossing, or an S- or U-shaped distortion.
The vein may have the appearance of an arch or hump called a Salus' Sign
if it passes in front of a sclerotic arteriole. The degree of compression is
commonly graded I-IV. When Grade III, the venular column is partially
obscured and appears tapered on each side of the crossing; when Grade IV,
there is interference with the venous return and peripheral distention of
the venule (Gunn's Sign, or "banking").
3. Vessel tortuosity. Loss of elasticity, thickening and lengthening cause
increased tortuosity of both arterioles and venules.
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4. Choroidal changes. These have been somewhat neglected in the litera-
ture concerning hypertension, probably because of their predominantly
peripheral visualization in the fundoscopic examination. They are more
often seen in the presence of severe hypertension, are ascribed to vascular
sclerosis in the choroid, and are commonly associated with neuroretinopa-
thy, though not necessarily so. In our experience, they have indicated a
bad prognosis for the patient. They are evident as pigmentary changes
visible in the choroid, through the peripheral retina, and are classified by
Duke-Elder' as follows:
(a). Pale yellow or reddish plaques surrounded by pigmentary deposits.
(b). Black, isolated flecks of pigment with bright red or yellow halos
(Elschnig's spots).
(c). Chains of pigmented spots arranged like a string of beads along a-
white, sclerosed vessel (Siegrist spots).
(d). Large patches of chorioretinal atrophy.
The distinction between vasospastic and arteriolar sclerotic changes in
the fundus, outlined in detail above, is carried out in the classification sug-
gested by Scheie, given below. The vasospastic changes parallel, in general,
the clinical severity of the hypertension, whereas the arteriolar sclerotic
changes give an indication of the sequential morphological vessel damage
associated with prolonged or severe hypertension. The former are more
potentially reversible than the latter. Scheie's System (choroidal changes
are not included):
Vasospastic (hypertensive)
Arteriolar narrowing
recognizable
Arteriolar narrowing
more marked; localized
irregularities
Accentuation of Grade II
findings, accompanied by
retinal hemorrhages and/or
exudative patches
Findings as under Grade III
plus papilledema
Grade Arteriolar sclerotic
I Recognizable increase in
light reflex; minimal
A-V compression
II Increased light reflex,
more marked than in
Grade I
III Copper wire arterioles;
more marked A-V com-
pression than in
Grade II
IV Silver wire arterioles;
usually striking A-V
compression
466
Volume 27, June 1955Evaluation and management of hypertension GOODYER, ROSENTHAL,
JAEGER
DIFFERENTIAL DIAGNOSIS
Friedenwald' ' differentiated three other types of retinal vascular abnor-
malities potentially independent from one another and from the changes due
to hypertension which have been described above.
1. The vascular changes of senescence. These should be differentiated
from pathological, degenerative vascular disease, such as atherosclerosis
which may not be inevitable. The fundoscopic picture of senescence is char-
acterized by narrow, straight vessels with diminished light reflexes and a
loss of retinal luster. Choroidal changes at the disc, in the macula, and in
the periphery are common, being caused by fibrosis and hyalinization of
the choroidal capillaries.
2. Atherosclerosis causes focal pathology usually not directly visible,
having a predilection for the central retinal artery as it passes through the
cribiform membrane. If the lumen is partially obstructed, the more periph-
eral arterial tree is narrowed. Occasionally, the actual atheroma may be
observed at the disc, appearing as a local constriction or opaque spot in
the vessel wall. If the lumen is occluded, a retinal infarct usually results,
characterized by a segmental area of pale coagulation necrosis along the
distribution of the occluded vessel. Central arterial thrombosis causes a
cherry-red spot in the macula with surrounding pale necrosis. Because of
the intimate association of artery and vein, intimal atherosclerosis may
invade the vein, causing venous obstruction or thrombosis even though the
artery remains patent. Widespread hemorrhagic retinal congestion and
edema result. Fibrosis of an atheroma in the retinal artery may cause
longitudinal shrinkage of the vessel, straightening the artery and narrowing
its angle of bifurcation and/or drawing the retinal branches toward the disc.
3. Diabetic retinopathy. Recent studies by Ballantyne and Loewenstein,'
and by Friedenwald' and Ashton' have shown that the typical lesion in
diabetic retinopathy is the capillary aneurysm, affecting mostly the deeper
capillary network, in contrast to the more superficial capillary involvement
in hypertension. These microaneurysms appear as "punctate hemorrhages,"
in contrast to true hemorrhages which though occasionally punctate are
usually more flame-shaped. They are almost specific for diabetes. True
hemorrhages and waxy exudates may also be seen with diabetes, due to
damaged capillaries. The extent of diabetic retinopathy is more clearly
correlated with the duration of the disease than with its age of onset,
severity, or the nature of its treatment.
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PART III. MEDICAL TREATMENT OF HYPERTENSION
On the basis of the evaluations of etiology and prognosis discussed in
Parts I and II, one or more of the various forms of therapy of hypertension
may be applied. In some cases, treatment of the specific etiologic agent,
or such simple measures as reassurance, weight reduction, or mild sedation,
may be sufficient. However, in cases of more severe hypertension of un-
known or unremediable origin, hypotensive medications may be indicated.
Therefore, before presenting a general plan for the management of the
various grades of hypertensive disease, it will be helpful to review the
properties, side reactions, and clinical use of some of the newer hypotensive
drugs. The pharmacological actions of these drugs are summarized in Table
TABLE C. SUMMARY OF THE PHARMACOLOGICAL AcrIoNs OF HYPOTENSIVE AGENTS
R (Raudixin-Reserpine Group); V (Veratrum Alkaloids); Co (Hexa-
methonium and Ansolysen); Ap. (Apresoline); + indicates a stimulant
effect, - a depressant effect on a scale of 0 (absent) to 3 (marked).
R V C6 Ap.
CNS 3- 1- 0 2+
Symp. Reflexes 0 0 2- 2+
p-Symp. Reflexes 1+ 2+ 2- 0
Aortic Reflexes 0 2+ 0 0
Epinephrine 0 0 0 0
Renal Circulation 0 0 1- 2+
Water Excretion 1- 1- 3- 2+
Heart Rate 1- 2- 1+ 2+
GI Tract and Bladder 1+ 3+ 3- 1+
Peripheral Vessels 0 0 0 3-
C, their clinical preparations and dosages in Table D, and their toxicity
and contraindications in Table E.
1. THE RAUWOLFIA DRUGS
Rauwolfia Serpentina, one of the 40 or 50 species of Rauwolfia, has been
used in India for a long time for anxiety states, hypochondriasis, insomnia,
insanity, snake bites, and dysentery.' Its mild hypotensive effect was dis-
covered by Indian workers in 1931." Three forms of this drug are in most
current use: the crude root (Rauwolfia Serpentina), a purified alkaloid
(Reserpine), and an alseroxylon fraction (Rauwiloid). These preparations
are only mild hypotensive agents, their widespread use being related to the
simplicity and safety of their administration and to their relatively few
undesirable or serious side effects.
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Pharmacological action (see also Table C). The hypotensive, tranquiliz-
ing, and sedative properties of the Rauwolfia compounds are thought to be
due, at least in large part, to their action at the level of the hypothalamus.
Most patients observe a sense of well-being, improved sleep pattern, and
decreased excitability and anxiety.
Toxicity and contraindications. The only serious untoward reaction
reported so far has been a rare psychosis characterized by severe anxiety
and depression. Other toxic effects are listed in Table D. Frequently, these
side effects may be eliminated by reduction of dosage or by brief interrup-
tion of the drug.
Dosage and clinical use. The effects of Rauwolfia or its derivatives are
gradual in onset and cumulative. The hypotensive effect may not become
maximal until one to eight weeks after onset of therapy. These preparations
are therefore given in daily doses (see Table D) which are reduced when a
therapeutic response is obtained.
Fixed, severe, or malignant hypertension seldom responds to Rauwolfia
alone. LoefflerT' treated 51 severe or malignant hypertensives with this drug
and observed prolonged reduction in blood pressure in only four patients.
Hensler," in treating a group of 60 hypertensives, observed no significant
improvement in six cases of nephritis or in three cases of malignant nephro-
sclerosis. Hypotensive effects of Rauwolfia were observed in only 39%o of
218 patients treated by five different groups in America and Europe.l9""""5"'
The Rauwolfia drugs, therefore, cannot be considered as highly effective
hypotensive agents in themselves. Nevertheless, they are the drugs of choice
in initiating hypotensive treatment, particularly because they often markedly
decrease the severity of unpleasant side effects and the total dosage require-
ments of the more potent agents.
I. VERATRUM COMPOUNDS
Veratrum has been known to possess emetic properties since the early
1800's, its hypotensive effect in eclampsia having been recognized as early
as 1860.8 There was little clinical use of this drug until 1949 at which time
various purified extracts (see Table D) were obtained which caused less
disagreeable side effects than the crude preparation.
Pharmacological action (see also Table C). The hypotensive effect of
veratrum is thought to be mediated through the central nervous system by
blockade of carotid and aortic receptors and by peripheral vasodilata-
tion.'8"9 125 The drug has little or no primary sympatholytic or para-
sympathomimetic activity, and causes only minor changes in renal function.
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TABLE E. TOXICITY AND CONTRAINDICATIONS OF THE HYPOTENSIVE DRUGS
Drug and chief
site of action
Rauwolfia Cmpds.
Hypothalamic
"tranquilization"
Veratritm Cmpds.
Blockade of carotid
and aortic receptors;
peripheral vasodilatation
Apresoline
Blockade of sympathetic
outflow from hypo-
thalamus;
Direct'peripheral vaso-
dilatation
Hexarnethoniu-m and
Ansolysen
Blockade of autonomic
ganglia
Serious
Psychosis
Circulatory
collapse
Increased
coronary
insufficiency
Lupus-like
syndrome
Cardiovascular
collapse
Paralytic
ileus
Interstitial
pneumonia
Severe renal,
cerebral or
myocardial
ischemia
Toxicity
Frequent
Nasal congestion
Bradycardia
Sedation
Increased appetite
Nausea & vomiting
Esophageal burning
Increased saliva-
tion
Bradycardia
Severe headaches
Nervousness
Nausea & anorexia
Diarrhea
Malaise
Weakness
Muscle aches
Palpitations
Orthostatic hypo-
tension
Blurred vision
Constipation &
abdominal cramps
Dry mouth
Impotence
Infrequent
Bronchitis
Muscle & joint
pains
Diarrhea
Decreased libido
Nightmares
Premature con-
tractions
Muscle weakness
& stiffness
Depressed AV con-
duction
Hiccup
Postural hypoten-
sion
Fever
Numbness & tingling
of extremities
Dizziness
Urticaria
Edema
Lacrimation
Depression & anxiet2
Aspermia
Rheumatoid
arthritis
Grippe-like state
Contraindications*
None
Chronic, severe
uremia
Severe cerebral
arteriosclerosis
Chronic uremia
Angina pectoris
(occ.)
r Congestive heart
failure (occ.)
Anorexia, nausea Severe coronary
& vomiting or cerebral ar-
Diarrhea teriosclerosis
Dizziness Chronic uremia
Fatigue (NPN above
Nocturia 80)
Urinary retention Unreliable or un-
intelligent
patient
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Toxicity and contraindications. The margin between the hypotensive
effect and the toxic symptoms of veratrum is very small although few, if
any, deaths have been attributed directly to the drug. Not infrequently the
response to a constant therapeutic dosage varies so much from day to day
that nausea and vomiting once or twice a week cannot be avoided. Acquired
DIAGRAM II. CHANGES OF MEAN RECLINING AND STANDING BLOOD PRESSURE
(MM. HG). AVERAGE VALUES DURING THE MONTH PRIOR TO TREATMENT
COMPARED TO THE AVERAGE VALUES DURING 2-18 MONTHS OF
DRUG TREATMENT IN 43 PATIENTS
Legend: Controls indicate variations of blood pressure in the same patients later
treated with drugs during periods without specific drug treatment. Hatched blocks
indicate standard deviations of changes of systolic (S) and diastolic (D) blood
pressure, the clear breaks indicating mean changes of each group, the dots repre-
senting the ranges. The changes of reclining blood pressure are significant (P < .01)
for Apresoline (S & D). The changes of standing blood pressure are significant for
Apresoline (S & D), Ansolysen and Ce (S & D), and the Veratrum drugs (S & D).
tolerance has not been reported. The most frequent side effects, listed in
Table E, occur in close relation to therapeutic hypotensive activity. Con-
sequently, the possibility of developing a potent hypotensive extract with-
out unpleasant toxic effects remains remote. Efforts to alleviate these toxic
symptoms by the use of atropine, belladonna, thorazine, dramamine, seda-
tion, and Rauwolfia or its derivatives have not been successful. The vera-
trum preparations are best reserved for moderately severe and malignant
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hypertensives (see Diagram II), but are usually ineffective in patients with
chronic severe uremia (NPN above 90 mg.%), or with severe cerebral
arteriosclerosis.
Dosage and clinical use. The recommended dosage depends upon the
specific preparation employed and usually varies from one to five tablets
three times daily (see Chart I). Only 9 of 18 patients treated for 2-11
months in this clinic have been able to tolerate continued therapeutic doses
of Vergytril or Protoveratrine. Statistically significant blood pressure
reduction was observed in all 18 patients (see Diagram II), but toxic
symptoms were frequent. Occasionally, left ventricular failure, retinopathy
and headaches decreased, electrocardiographic abnormalities became less
evident, and gallop rhythm, palpitations and angina subsided.
111. L-HYDRAZINOPHTHALAZINE
Hydralazine compounds characterized by a heterocyclic phthalazine ring
and a hydrazine group have been shown to reduce blood pressure in experi-
mental animals'1 and in human subjects.2'
67 79, 8 100, Of all the compounds
tested, L-hydrazinophthalazine (Apresoline) has had the most extensive
clinical trials and has the best effects on blood pressure with the least
toxicity.
Pharmacological action (see Table C). The hydralazines react with sulf-
hydryl radicals, carbonyl radicals, glucose and heavy metals, and are con-
sidered antienzymes, inhibiting amine oxidase, histaminase, and DOPA
decarboxylase. In therapeutic dosage, they cause little or no peripheral
adrenergic blockade (adrenolytic or sympatholytic) but increase cardiac
rate and output, and inactivate certain humoral pressor substances such as
pherentasin (said to be present in the blood of hypertensives, but not in
normal blood).' The most powerful hypotensive action has been thought to
be via suppression of sympathetic vasopressor impulses from the hypothala-
mus. However, recent evidence indicates a more important direct peripheral
action causing dilatation of constricted vascular smooth muscle. In acute
experiments, Apresoline increases renal blood flow, while glomerular filtra-
tion is unaffected. However, the renal function of patients with chronic
severe renal damage is usually unimproved by the drug.'
Toxicity and contraindications. When Apresoline is employed as the sole
anti-hypertensive agent, side effects are frequent (see Table E), the most
serious being of cardiovascular origin. By augmenting the cardiac output
and causing tachycardia, the drug may increase the coronary insufficiency
of these patients with pre-existent coronary arteriosclerosis. ST-T segment
depressions and T-wave changes closely resembling those of myocardial
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anoxia may be observed during the hypotensive response to Apresoline.
Acute myocardial infarction has been described within 20 minutes of a dose
of the drug.'0 The cardiac effects of the drug may also tend to increase con-
gestive heart failure. Another serious toxic effect is the collagen disorder
closely resembling acute lupus erythematosis-even to the finding of typical
LE cells in the peripheral blood and bone marrow.92'"10 Fortunately, this
reaction, unlike true lupus, rapidly subsides when Apresoline is discon-
tinued. Severe headaches may be very annoying during initiation of treat-
ment, but usually subside as treatment is continued. Increased nervousness,
nausea, and diarrhea are frequent, and, though not serious, may force
discontinuance of therapy.
Dosage and clinical use. At the present time it is impossible to select in
advance those patients who will respond to Apresoline. It has been sug-
gested that neurogenic hypertension is more likely to respond than the
hypertension associated with primary renal disease.1"5 The drug is better
tolerated if given four times daily (after meals and at bed time). The usual
initial dosage of 10 mg. q.i.d. is gradually increased to 50 mg. q.i.d. and
then is further increased by increments of 50 mg. per dose until a satis-
factory blood pressure response is observed, or until a total daily dose of
800 mg. has been reached. Dosages above 800 mg. usually increase the toxic
effects without causing significant further reduction of the blood pressure.
Treatment should be continued for at least five weeks before any lack of
hypotensive effect is interpreted as a therapeutic failure. If a good response
is obtained, the dosage should subsequently be reduced to the least amount
consistent with a desired therapeutic or hypotensive effect.
Over a long period, tolerance to the drug commonly develops, as indi-
cated by diminished side effects and less hypotensive response, in spite of
gradually increasing dosage.
IV. AUTONOMIC GANGLION BLOCKING AGENTS
In 1950, Smirk reported extensive experimental studies and encouraging
clinical results in hypertensives with hexamethonium (C6). This compound
blocks the sympathetic and parasympathetic ganglia causing hypotension by
general release of vasoconstrictor tone.116'' In the search for other drugs of
similar action with fewer side effects, the bitartrate salt of 1-methyl-
pyrrolidinium was found to have the most satisfactory hypotensive effect. It
has had rather extensive clinical trial by Smirk, and by Fries, and is now
commercially available under the trade name of Ansolysen.tm
n.n'
Pharmacological action (see Table C). Therapeutic dosage of either
hexamethonium or Ansolysen causes the following:
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1. Fall in systemic and pulmonary blood pressures
2. Drop in peripheral resistance
3. Increase in blood flow and skin temperature of the extremities
4. Inhibition of gastric and salivary gland secretions
5. Disturbance of eye accommodation
6. Decrease in renal blood flow.
The hypotensive effects are most pronounced when the patient is upright,
and are quite minimal when the patient is supine.
Toxicity and contraindications. Toxic effects of Ansolysen are similar to
those of C6 (see Table E), although less severe, probably because the
dosage of Ansolysen is more easily controlled (see below). Cholinergic
drugs such as pilocarpine nitrate and urecholine are of slight value in con-
trolling side effects-particularly those related to the urinary, gastro-
intestinal, and visual systems. Reading glasses may be necessary to relieve
blurring of vision in patients whose professions or occupations require clear
vision. Because of pupillary paralysis, tinted glasses may be necessary dur-
ing exposure to sunlight. Important contraindications to both drugs are
listed in Table E. In general, these contraindications are more absolute for
Co than for Ansolysen.
Dosages and clinical use.
A. Hexamethonium (C6) chloride. Oral dosage of C6 is difficult to regu-
late because of incomplete and variable intestinal absorption of the drug and
because of the rapid development of drug tolerance. Changes of environ-
mental temperature, physical activity, and daily meals, or the consumption
of alcohol, tend to cause marked fluctuations in the hypotensive response to
a constant daily oral dose. It is therefore advisable, where possible, to begin
treatment while the patient is under close observation in the hospital (not
at bed rest), and to instruct the patient or a member of his family in the
technique of measuring his blood pressure. Ambulatory treatment may be
started by administering 125 mg. q.i.d. (expressed in terms of hexametho-
nium chloride). The dose is increased to 250 mg. q.i.d. during the first
week, and thereafter by weekly increments of 250 mg./dose until an ade-
quate hypotensive response (as indicated by the standing blood pressure)
is obtained, or until distressing side effects force discontinuance of the drug.
The therapeutic aim should be to reduce the blood pressure toward normal,
while avoiding symptomatic or prolonged hypotension.
Parenteral dosage of C6 is somewhat more reliable in its effects than oral
dosage for reasons indicated above. Although the drug may be administered
intravenously in hypertensive emergencies, it is better given subcutaneously
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about every 8 hours, particularly where continued parenteral treatment is
contemplated. Maintenance therapy can be continued indefinitely at home
by proper instruction of the patient (or a relative) in the technique of
TABLE F. RECOMMENDED MEDICAL THERAPY OF HYPERTENSION
Severity of disease
(1) Mild labile hypertension
with diastolic pressures
between 100 and 110
mm. Hg (Grade I)
(Smithwick)
(2) Fixed mild hypertension
with diastolic pressures
between 100 and 120
mm. Hg (Grade II)
(Smithwick)
(3) Fixed moderately severe
hypertension with dias-
tolic pressures above
120 mm. Hg-not ma-
lignant (Grade III)
(Smithwick)
(4) Malignant hypertension
(Grade IV) (Smith-
wick)
(5) Hypertension with renal
failure (NPN>50)
(6) Hypertensive emergencies
Initial treatment
Weight reduction
Reduce responsibilities
Phenobarbital
Rauwolfia serpentina
or derivatives
Rauwolfia serpentina
or derivatives
Veratrum drugs or
Apresoline
200 mgm. Na diet (or
rice diet)
Combination of Apreso-
line with hexametho-
nium or Ansolysen
200 mg. Na diet (or
rice diet), if no salt-
wasting. Veratrum
drugs (NPN<90)
Intravenous drug thera-
py (Veratrum drugs,
hexamethonium or
Ansolysen)
Supplementary treatment
Rauwolfia serpentina or
derivatives
Selective psychotherapy
Low Na diets, Veratum
drugs or Apresoline
Hexamethonium chloride
or Ansolysen
200 mgm. Na diet (or
rice diet)
Intramuscular drugthera-
py (Co or Ansolysen)
Apresoline not recom-
mended
Ansolysen and Ca to be
used with great caution
sterile injection, and in the regulation of dosage according to frequent
measurements of the standing blood pressure. Parenteral therapy is best
begun with a 2 mg. dose (expressed in terms of the hexamethonium ion),
the patient being kept in a semi-sitting position in order to determine the
degree of orthostatic hypotensive effect. Each dose is then increased 5 to
10 mg. at 6-8 hour intervals until optimal and stable hypotensive effects are
attained. Any profound fall in blood pressure should be counteracted by
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immediate postural readjustment (to the supine or'head-down position), or
by using vasoconstrictor drugs (e.g., methoxamine hydrochloride, or
arterenol by infusion).
B. Ansolysen. During recent years, this drug has largely supplanted
hexamethonium chloride, particularly in the treatment of moderately severe
and malignant hypertension,"7"'9 because of its more complete and constant
absorption from the intestines, and because of its allegedly more prolonged
action.7 As compared with hexamethonium (on the basis of parenteral
vwq 8
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FIG. 1. Female patient with severe hypertension associated with polycystic kidneys
and following poliomyelitis. Blood pressure responded well, and "score" (by the
method of Table A) changed from 13 to 5.
administration), it is thought to be 2-4 times more active on the sympa-
thetic, and 1-2 times more active on the parasympathetic nervous systems.
Oral administration may be safely begun in ambulatory patients with doses
of 20-40 mg., a.c., q.i.d., and then increased by daily increments of 10-20
mg./dose until the desired hypotensive effects are obtained. Precautions
similar to, but less strict than, those outlined for hexamethonium are
advisable.
Parenteral administration is unnecessary for maintenance therapy but
may be indicated for hypertensive emergencies. In such cases, the drug is
given intravenously or subcutaneously in the same way as has been
described above for C6, but in smaller doses, careful control of the semi-
sitting blood pressure being required. The dosage is increased at 6-8 hour
intervals in increments of 2 mg./dose, after an initial dose of 2 mg. Because
of the potential hazards of any autonomic blocking agent, Ansolysen-even
though more easily administered than hexamethonium-should also be
reserved for patients with severe hypertension (see Table F).
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V. THE USE OF THE HYPOTENSIVE DRUGS UNDER SPECIAL CIRCUMSTANCES
A. Hypertension in pregnancy. Toxemia of pregnancy may be defined as
a disease characterized by hypertension, edema, and albuminuria which is
peculiar to pregnancy, usually occurring during the third trimester (see
Part I). Since its pathological physiology involves widespread arteriolar
vasoconstriction and decreased blood flow to major organs such as the
kidneys, uterus, and brain, therapy logically includes measures directed
toward arteriolar dilatation. The ordinary sedatives are useful in this
8.T. age 36
W.F
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50 -. _
2
RAUDIXIN t300-100 mgm
APRESOLINE t25-150mgm
PROTOVERATRINE 12.Smgm -T
RESERPINE DRUGS t 1.0mgm
FIG. 2. Female patient with severe essential hypertension. Blood pressure reduced,
papilledema reversed, and score changed from 16 to 9 with a succession of medications.
Apresoline had to be stopped because of severe nasal stuffiness and anxiety state.
regard, and intravenously administered magnesium sulfate (which has
sedative as well as hypotensive actions) is useful in "pre-eclampsia" or
"eclampsia." However, it seems logical to attempt to alleviate toxemic
hypertension and its related symptoms with more purely hypotensive agents,
in order to avoid deleterious depressant effects of oversedation on the
infant, and in order to allow adequate clinical observation for other un-
toward (particularly cerebral) symptoms. For this purpose, the usefulness
of the Veratrum compounds has been indicated in extensive clinical trials
in which mortality from toxemia seems to have been reduced."32 Apresoline,
which lowers the blood pressure and increases renal functions, cerebral
blood flow, and cardiac output in toxemia,2 also appears to be a suitable
agent for the treatment of this disease. The ganglionic blocking agents effec-
tively reduce toxemic hypertension, but have the disadvantage of impairing
renal flow and glomerular filtration, and cerebral blood flow. They have
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been used, therefore, chiefly in cases of toxemia superimposed on essential
hypertension.
B. Hypertensive crises. Acute hypertensive crises, such as encephalopa-
thy or acute pulmonary edema may be managed by cautious use of
intravenous Veratrum or ganglionic blocking agents, administered in
graded doses well diluted in a suitable vehicle such as saline or 5% glucose
(see the discussions of each drug for further details). As indicated previ-
ously, lowering of the blood pressure in this way is more likely to relieve
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FIG. 3. Female patient in the incipient phase of malignant hypertension, with a recent
cerebral vascular accident, whose blood pressure responded well and whose score
changed only from 21 to 18 in three months of therapy.
acute pulmonary edema, which usually tends to be functionally reversible,
than to relieve encephalopathy, which is often the concomitant of fulminant
vascular disease and/or uremia.
VI. THE USE OF THE HYPOTENSIVE DRUGS IN CONJUNCTION WITH LOW SODIUM
DIETS
The impressive work of Kempner has prompted extensive interest in the
use of low sodium diets in the treatment of hypertension.' The effectiveness
(30-50%o) of the various low sodium diets has been confirmed, but few
patients in their normal environments are able to tolerate the stringent
deprivations which are required. The critical level of sodium intake for ade-
quate treatment of hypertension is about 200 mg. of sodium per day. Diets
which contain more than this quantity of sodium are probably ineffective in
the management of essential or malignant hypertension except in controlling
479
I I -1 11-- .-
'48'51 '521%31'54112468 10 12 14 16
I I 11 I I I I
. .. I I IYALE JOURNAL OF BIOLOGY AND MEDICINE Volume 27, June 1955
congestive heart failure. Serious complications such as the development of
the low sodium syndrome, renal failure, or severe metabolic acidosis, are
unusual except in patients with marked renal impairment. However, side
effects such as weight loss, weakness, and mental depression are frequent.
In spite of the above disadvantages, the low sodium diet may be very
useful in selected cases to potentiate the effects of the autonomic blocking
agents if the latter have been partially or even completely ineffective.
VII. AN OVER-ALL PLAN FOR THE MEDICAL MANAGEMENT OF VARIOUS GRADES OF
HYPERTENSION
In the previous sections, the actions and uses of individual drugs have
been discussed. In practice, it is usually desirable to combine one or more
drugs with more general supportive measures in order to take advantage of
complimentary hypotensive effects, while avoiding the side effects associ-
ated with the larger doses of each preparation. Table F suggests, in outline,
a plan for such combined therapy. Representative cases illustrating success-
ful results of combined drug therapy are illustrated in Figures 1-3. The
average responses of blood pressure to various drugs in 56 patients are
given in Diagram II. Seventy per cent of these patients had "essential
hypertension." Thirteen per cent had malignant hypertension (scores of 21
or more, according to criteria of Table A), 40% had severe hypertension
(scores 14-20), 36%o had moderate hypertension (scores 8-13), and 91%
had mild hypertension (scores 1-7).
It would seem from our experience summarized in Diagram II that
Apresoline, Veratrum, and the autonomic blocking agents have been useful
in lowering the standing blood pressure of many patients. However, the
ultimate long-term value of the use of such drugs, particularly with respect
to the reversal or interruption of the course of organic vascular disease,
remains to be proven.
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